Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Sexual dysfunction—including erectile dysfunction, ejaculatory abnormalities and orgasmic disorders—is a commonly reported adverse effect of prostate cancer therapies. In this Perspectives article, Cormie and colleagues make a case for the use of exercise as a therapeutic option to ameliorate sexual dysfunction in prostate cancer survivors.
Despite its prevalence, morbidity and mortality, bladder cancer remains grossly under-recognized as a public health concern and underfunded scientifically. In this article, Kaplanet al. discuss bladder cancer awareness and funding pitfalls, physician reimbursement policy, areas of future research and the integration of bladder cancer into the coordinated health-care era.
In this Perspectives article, Elterman et al. discuss the health inequalities that face men in the 21st century and consider ways in which urologists can lead the emerging subspecialty of 'male health'.
In this Perspectives article, Rodriguez-Nieves and Macoska discuss relationships between prostatic tissue inflammation (from ageing, infection, or other inflammatory disease processes), prostatic tissue fibrosis, lower urinary tract dysfunction (LUTD), and BPH, as well as highlighting recent advances in the use of antifibrotic therapeutic agents for treating LUTD.
In this Perspectives article, Centenera et al. chronicle the development of ex vivoculture models that utilize tumour material from men with prostate cancer and discuss the advantages, limitations, and potential applications of these systems to expedite the evaluation of novel drugs for the treatment of prostate cancer.
In this Perspectives article, the author presents his theory that pressure has shaped the morphology of the prostate over time, and discusses the implications this might have on the longstanding debate of the relationship between BPH and prostate cancer.
Increasing evidence has shown that a solid tumour can 'hijack' pre-existing blood vessels and integrate them into the tumour vasculature during expansion. In this Perspectives article, Chao-Nan Qian argues that this process—vessel co-option—likely occurs in clear cell renal cell carcinoma, along with the complementary processes of vessel remodelling and extratumoural angiogenesis.
